Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis. Dubey D, Cano CA, Stüve O Curr Opin Neurol. 2016 Mar 29. PMID: 27027553. Abstract CommentRecommendBookmarkWatch